News | Radiation Therapy | October 25, 2017

MR-Guided Radiotherapy Prolongs Median Survival for Inoperable, Locally Advanced Pancreatic Cancer

Study indicates higher dosing enabled by MR-guidance combined with daily on-table adaptation led to significant potential clinical benefits for pancreatic cancer patients

MR-Guided Radiotherapy Prolongs Median Survival for Inoperable, Locally Advanced Pancreatic Cancer
MRIdian MRI-guided radiotherapy overall survival for pancreatic cancer patients

Early clinical data suggests nearly 2X prolonged median survival for inoperable, locally advanced pancreatic cancer with MRIdian MR-Guided Radiation Therapy. Image from “Higher Maximum Biological Effective Dose Utilizing Adaptive MRI Guided Radiation Therapy Improves Survival of Inoperable Pancreatic Cancer Patients. Rudra S, Jiang N, Rosenberg S, Olsen J, Lagerwaard F, Bruynzeel A, Parikh P, Bassetti, M, Lee P, ASTRO 2017”

October 25, 2017 — ViewRay Inc. announced outcomes data presented during the recent 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego. This data highlighted compelling early results using the company's magnetic resonance imaging (MRI)-guided MRIdian radiation therapy system for the treatment of inoperable, locally advanced pancreatic cancer.

MRIdian allows clinicians to see the tumor and nearby soft-tissue anatomy throughout radiation treatments using real-time diagnostic MR-visualization. As a result, MRIdian's on-table adaptive radiation therapy allows doctors to respond to subtle anatomical changes observed on a day-to-day basis and reshape the dose to better match the current contours of the tumor. By more accurately targeting the tumor, and reducing treatment radiation dose to surrounding organs such as the duodenum, small bowel, stomach and liver, a higher and potentially more effective radiation dose may be delivered without increasing the risks of side effects and complications for the patient.

As featured in the ASTRO Scientific Session poster titled "High Dose Adaptive MRI Guided Radiation Therapy Improves Overall Survival of Inoperable Pancreatic Cancer," key data points and findings from the presentation include the following:

  • The study detailed a retrospective review of 42 locally-advanced pancreatic cancer patients treated with MRIdian at four institutions (University of California Los Angeles, University of Wisconsin, VU University Medical Center, Washington University);
  • The authors examined survival and toxicity rates for two unique cohorts of patients. One sample received a higher biologically effective dose (maxBED10 >90), primarily enabled by MRIdian MR-guided on-table adaptive radiotherapy. The other sample received a lower, more conventional biologically effective dose (maxBED10 <90), using non-adaptive therapy;
  • The cohort receiving a higher dose demonstrated a near doubling of median overall survival (Kaplan-Meier estimated median overall survival of 27.8 months compared to 14.8 months); and
  • Patients treated with higher radiation doses reported no grade 3 or higher toxicities (0 percent). In comparison, those patients receiving lower doses via non-adaptive treatments experienced 15.8 percent grade 3 or higher toxicities.

"High-definition MR now enables oncologists to detect the slightest anatomical changes that occur from one day to the next and in real-time while the patient is being treated. Coupled with new adaptive radiation therapy software tools, we create new customized plans in minutes, all while the patient is on the treatment table," said Percy Lee, M.D., senior author and associate professor and vice chair of education for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA. "The data presented at the 2017 ASTRO Annual Meeting suggests that higher radiation doses with adaptive MR guided radiation therapy may improve survival in pancreatic cancer while maintaining a very favorable toxicity profile. These outcomes warrant further investigations."

The early results highlighted above, along with other data obtained using MRIdian, will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer. The trial will be conducted by ViewRay's Clinical Cooperative Think Tank (C2T2), a group of MRIdian medical institutions focused on evidence gathering to support MR-guided radiation therapy.

For more information: www.viewray.com

Related MRI-Guided Radiotherapy Content

WEBINAR: Pancreatic Cancer Outcome Highlights via On-table Adaptive MR-guided Radiation

Related Content

Sponsored Content | Videos | Radiation Therapy | November 15, 2017
Chris Toth, president, Oncology Systems Americas, takes a tour of Varian’s new product introductions and major initia
Philips Azurion Image-Guided Therapy Platform Improves Clinical Workflow for Interventional Procedures
News | Angiography | November 15, 2017
Philips announced the results of a comprehensive, independent, two-year study demonstrating the clinical workflow...
Study Unveils Brain Changes During Extended Space Missions
News | Neuro Imaging | November 14, 2017
November 14, 2017 — More people today are poised to explore space than ever before; those who do will experience the
Synthetic CT Images Suitable for Prostate Cancer Radiotherapy Planning
News | Treatment Planning | November 14, 2017
Spectronic Medical announced that new data for their MRIPlanner software, generating synthetic computed tomography (sCT...
News | Magnetic Resonance Imaging (MRI) | November 13, 2017
Aspect Imaging announced last week that it received CE marking for the neonatal-dedicated Embrace Neonatal Magnetic...
Hitachi Healthcare Highlights Benefits of High-Field Open MRI in New Supplement

Click here to view the supplement.

News | Magnetic Resonance Imaging (MRI) | November 13, 2017
A new 24-page publication from Hitachi Healthcare details the benefits of High-Field Open MRI and is now available for...
Siemens Healthineers Introduces Share360 Tailored Service Portfolio
News | Imaging | November 10, 2017
November 10, 2017 — To address the specific needs of...
Johns Hopkins Researchers, Carestream Give Presentations on Medical Imaging Advances at RSNA
News | Digital Radiography (DR) | November 09, 2017
November 9, 2017 — Researchers from The Johns Hopkins University School of Medicine and Carestream Health scientists
ASTRO: CMS Report on Radiation Therapy Payment Model Charts Path to Value-Based Cancer Care
News | Radiation Therapy | November 08, 2017
The American Society for Radiation Oncology (ASTRO) called on the Centers for Medicare and Medicaid Services (CMS) to...
3D CT image reconstruction of the thoracic organs and the heart using Philips software.
Sponsored Content | Webinar | Advanced Visualization | November 07, 2017
The CME webinar “Innovation and Success in 3D-inspired Development of the Business and Clinical Practice,” will take
Overlay Init